1. Home
  2. TRNO vs TGTX Comparison

TRNO vs TGTX Comparison

Compare TRNO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Terreno Realty Corporation

TRNO

Terreno Realty Corporation

HOLD

Current Price

$64.33

Market Cap

7.0B

Sector

Finance

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$40.16

Market Cap

6.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRNO
TGTX
Founded
2009
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.0B
IPO Year
2009
2008

Fundamental Metrics

Financial Performance
Metric
TRNO
TGTX
Price
$64.33
$40.16
Analyst Decision
Buy
Strong Buy
Analyst Count
12
5
Target Price
$67.83
$49.80
AVG Volume (30 Days)
651.8K
1.8M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
3.21%
N/A
EPS Growth
103.65
1746.67
EPS
0.66
0.12
Revenue
$476,383,000.00
$2,785,000.00
Revenue This Year
$8.42
$49.08
Revenue Next Year
$9.10
$26.69
P/E Ratio
$97.73
$338.00
Revenue Growth
24.51
N/A
52 Week Low
$53.00
$25.37
52 Week High
$67.55
$44.65

Technical Indicators

Market Signals
Indicator
TRNO
TGTX
Relative Strength Index (RSI) 45.60 58.67
Support Level $64.01 $38.20
Resistance Level $67.05 $44.65
Average True Range (ATR) 1.19 1.42
MACD -0.25 -0.14
Stochastic Oscillator 35.66 67.69

Price Performance

Historical Comparison
TRNO
TGTX

About TRNO Terreno Realty Corporation

Terreno Realty Corp is a real estate investment trust engaged in acquiring, owning, and operating industrial real estate in six coastal U.S. markets: Los Angeles, Northern New Jersey/New York City, San Francisco Bay Area, Seattle, Miami, and Washington, D.C. The company invests in several types of industrial real estate, including warehouse/distribution, flex (including light industrial and research and development), transshipment, and improved land.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, it has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. Its pipeline includes UBLITUXIMAB, SUB-Q UBLITUXIMAB, and AZER-CEL. Geographically, it generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from the international market.

Share on Social Networks: